High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease
This article introduces an alternative immunodiagnostic approach based on the concept of a "tauosome" - the diverse set of tau fragments present within biological fluids. The development of an antibody panel that can distinguish a range of different tau fragments provides the basis for a novel approach to potential diagnosis and monitoring of disease progression. Our results further support the notion that tau immunotherapy targeting the PHF-core needs to combine appropriate selection of both the target epitope and antibody affinity to optimise therapeutic potential.
Authors
- Lewis K. Penny (ORCID: https://orcid.org/0000-0002-3722-4476)
- Charles R. Harrington (ORCID: https://orcid.org/0000-0003-2250-3920)
- Pietro Marini (ORCID: https://orcid.org/0000-0002-8456-4473)
- Mohammad Arastoo (ORCID: https://orcid.org/0000-0002-0805-4949)
- Anna Abrahamsson
- Aya Abdallah (ORCID: https://orcid.org/0000-0001-7594-5736)
- Soumya Palliyil (ORCID: https://orcid.org/0000-0002-6203-8106)
- A.J. Porter (ORCID: https://orcid.org/0009-0000-6633-9179)
- Claude M. Wischik
- Richard Lofthouse (ORCID: https://orcid.org/0000-0002-7327-9490)
- Gernot Riedel (ORCID: https://orcid.org/0000-0002-2374-6281)
- Valeria Melis (ORCID: https://orcid.org/0009-0007-6926-1726)
Institutions
- University of Aberdeen (GB)
- TauRx (United Kingdom) (GB)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1186/s13195-024-01561-1
- Citations
- 7
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- University of Aberdeen